Bernstein lowered the firm’s price target on Guardant Health (GH) to $35 from $40 and keeps an Outperform rating on the shares. With the large, diversified tools companies taking a hit this earnings season, the firm sees the diagnostics names as the safe place to be in the sector. Broadly, reimbursement tailwinds from the biomarker bills continue to help ASPs in the sector, with California’s bill now live and the introduction of a new bill from Hawaii. On the regulatory front, the FDA LDT regulation was enacted in Q2, though legal challenges have been mounting as expected, Bernstein adds.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Appoints Roberto Mignone to Board
- Guardant Health price target lowered to $50 from $60 at Leerink
- Guardant Health publishes SCRUM-Japan GOZILA study results
- Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI
- Guardant Health, Italy’s Policlinico Gemelli team on liquid biopsy testing